Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Sigma Healthcare reports strong profit growth, shares fall despite solid results

For the year to June 2026 Sigma Healthcare recorded revenue up 15.5% to AUD 10.8 billion, normalized EBIT of AUD 1.098 billion (+20.6%) and normalized NPAT of AUD 732.3 million (+22.3%). The stock fell about 6.2% as investors highlighted extended cash conversion, integration costs and margin risks from strong GLP-1 category growth. Management reports realized synergies and continued store growth; the company expects ongoing revenue momentum and plans to deliver further synergies through 2029. » Altro su de.investing.com
Sigma Healthcare withdraws from $10 billion bid for Boots

Australia’s Sigma Healthcare has ended early-stage talks to acquire U.K. pharmacy chain Boots, saying the asset no longer fits its strategic priorities and it will focus on Australian and Asian growth. The withdrawal prolongs uncertainty over Boots’ ownership; the chain operates about 1,800 UK stores and has recently been repositioned toward higher-margin beauty and wellness categories. Boots’ owner Sycamore Partners is reported to be considering an IPO as alternatives to a sale continue to be explored. » Altro su forbes.com
Sigma Pharmaceuticals share falls after confirmation of talks about Boots

Sigma Pharmaceuticals’ share slid 5.5% to A$2.76 after the company confirmed it had taken part in early talks about a possible acquisition of the Boots pharmacy chain. The process is being led by Sycamore Partners and a valuation of around US$10 billion has been mentioned, but there is no certainty a deal will be completed. Investors are worried about the size and timing of such a transaction so soon after the merger with Chemist Warehouse because of potential integration, financing and execution risks. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, Sigma Healthcare ha già distribuito 0,0122 € di dividendi. L'ultimo pagamento è avvenuto a marzo.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Sigma Healthcare ha registrato ricavi pari a 3,13 Mld € e un utile netto di 215,93 Mln €

(EUR)	dic 2025	YoY
Ricavi	3,13 Mld	-
Utile lordo	572,94 Mln	-
Utile netto	215,93 Mln	-
EBITDA	333,2 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	19,03 Mld €
Numero di azioni	11,54 Mld
Massimo/minimo a 52 settimane	1,98 € - 1,60 €
Rendimento da dividendo	0,73%
Dividendi TTM	0,0122 €
Beta	0,34
Rapporto P/E	-302,84
Rapporto PEG	2,90
Rapporto P/B	5,00
Rapporto P/S	6,29

Profilo aziendale

Sigma Healthcare Limited ist zusammen mit seinen Tochtergesellschaften im Großhandel und Vertrieb von pharmazeutischen Produkten hauptsächlich in Australien tätig. Das Unternehmen betreibt rund 1.200 Markenapotheken und unabhängige Apotheken unter den Marken Amcal, Discount Drug Stores, Guardian, WholeLife und PharmaSave. Darüber hinaus bietet das Unternehmen Großhandelsdienstleistungen für Krankenhausapotheken, Hilfsdienste für die Verabreichung von Arzneimitteln in der Altenpflege, in Gemeindeapotheken und im häuslichen Bereich, Technologielösungen und Datenanalysen sowie Produktentwicklung und -unterstützung für eine Reihe von Eigen- und Exklusivmarkenprodukten an und liefert medizinische Verbrauchsmaterialien und Geräte an eine breite Palette von Kunden, darunter Apotheken, Altenpflegeeinrichtungen, Krankenhäuser und Kliniken. Darüber hinaus bietet das Unternehmen pharmazeutischen Herstellern und anderen Lieferpartnern Kontraktlogistikdienste an. Sigma Healthcare Limited wurde 1912 gegründet und hat seinen Hauptsitz in Rowville, Australien.